ADP-c389

ADP-c389 is a small-domain protein-drug conjugate (PDC) targeting the oncofetal cell surface receptor tyrosine kinase ROR1. Developed by Almac Discovery in collaboration with Elasmogen, ADP-c389 utilizes a small-domain protein platform to deliver a cytotoxic payload specifically to ROR1-expressing tumor cells. ROR1 is highly expressed in various solid tumors and hematological malignancies but is largely absent from normal adult tissues, making it an attractive target for selective therapy. In pre-clinical studies, ADP-c389 has demonstrated complete and sustained tumor regressions in patient-derived xenograft (PDX) models of triple-negative breast cancer (TNBC) and has shown efficacy across other solid tumor indications including non-small cell lung cancer (NSCLC), ovarian, endometrial, esophageal, and gastric cancers.